
ŌURA Announces Two New Heart Health Features, Moving Deeper into Preventative Health
New Cardiovascular Age and Cardio Capacity capabilities further establish ŌURA as a personal health companion for improving healthspan and longevity
Florida / New York
Ph: 561.316.3330
The medical device space is growing rapidly as new startups and investments from major players enter the market. Some of the most notable investors in medical devices include venture capital firms such as Kleiner Perkins Caufield & Byers, Sequoia Capital, and Accel Partners, as well as large companies such as Johnson & Johnson and Medtronic.
This influx of investment is driving innovation in the medical device space, with new devices and treatments being developed all the time. This growth is also creating opportunities for entrepreneurs, who can now launch their own medical device startups and access funding from major players.
New Cardiovascular Age and Cardio Capacity capabilities further establish ŌURA as a personal health companion for improving healthspan and longevity
A minimally invasive procedure, Epione uses CT-guided navigation for the percutaneous ablation of tumors in the abdomen.
“SonoVascular is honored to have the opportunity to partner with Lantheus, a leader in microbubble development,” said Daniel Estay, Founder and Chief Executive Officer of SonoVascular. “Our SonoThrombectomy System, combined with Lantheus’ microbubbles, is designed to provide a true, next-generation solution for the treatment of DVT and PE that overcomes the drawbacks associated with catheter-based thrombectomy and thrombolysis devices.”
Eureka α utilizes state-of-the-art AI to analyze real-time video from laparoscopic and robotic surgery, enhancing surgeons’ accuracy by highlighting the dissection planes characterized by connective tissue.
Reeva FT is offered in a variety of sizes: 2×2 cm, 2×3 cm, 4×4 cm, 4×6 cm, 4×8 cm, and 10×15 cm. Reeva FT is confirmed by the FDA Tissue Reference Group to meet the criteria for regulation solely under Section 361 of the PHS Act as defined in 21 CFR Part 1271.
The RWE Program will expand Summus Laser’s Class IV Laser Therapy research to generate validated and statistically significant datasets that will be used to enhance patient care, outcomes, and to further product innovations.
Copyright © 2025 Medical Device News Magazine, a division of PTM Healthcare Marketing, Inc. All Rights Reserved
Hours:
M – F 8 am – 5 pm
Florida / New York
Phone: 561.316.3330